SDR16C5

Across TCGA pan-cancer cohorts, SDR16C5 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SDR16C5 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher SDR16C5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SDR16C5 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUSC, SKCM, and UCEC are the cancer types where SDR16C5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	30	view →
SKCM	DFS	Median	II,III,IV	0.925	0.655	.004	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SDR16C5–LUSC (DFS)

Open the LUSC breakdown →